Chen-Hsiung Yeh
Chen-Hsiung Yeh has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Andrew Ford
3 shared publicationsJonathan Spurgin
Circulogene Theranostics, Homewood, AL
2 shared publicationsAshlee Stamba
Circulogene Theranostics, Homewood, AL
1 shared publicationCharmaine Brown
1 shared publicationChrista Lidikay
Circulogene Theranostics, Birmingham, AL
1 shared publication- Guru Sonpavde
AdventHealth Cancer Institute, Orlando, USA
1 shared publication
Latest Publications
- Open Access
- 18 January 2018
- Published by Lupine Publishers LLC in Open Access Journal of Oncology and Medicine
- Vol. 1 (1) , 001-004
Somatic Mutations in Cancer-Free Individuals: A Liquid Biopsy Connection
Over the course of our lifetime, there are many millions of cell divisions in the body. By chance alone, mutations will definitely occur. Indeed, spontaneous somatic mutations constantly
- 18 January 2018
- Published by Lupine Publishers LLC in Open Access Journal of Oncology and Medicine
- Vol. 1 (1) , 001-004
Open AccessSomatic Mutations in Cancer-Free Individuals: A Liquid Biopsy Connection
Over the course of our lifetime, there are many millions of cell divisions in the body. By chance alone, mutations will definitely occur. Indeed, spontaneous somatic mutations constantly
- Open Access
- 3 July 2017
- Published by Biomedical Research Network, LLC in Biomedical Journal of Scientific & Technical Research
- Vol. 1 (2)
When Liquid Biopsy Cell-Free DNA Meets with Tissue Biopsy RNA
The Biomedical Journal of Scientific & Technical Research is an open access medical and clinical research publication that gives acclaimed scientific authors and research experts a global platform to share their work among like-minded peers and help accumulate scientific knowledge in a singular repository.
- 3 July 2017
- Published by Biomedical Research Network, LLC in Biomedical Journal of Scientific & Technical Research
- Vol. 1 (2)
Open AccessWhen Liquid Biopsy Cell-Free DNA Meets with Tissue Biopsy RNA
The Biomedical Journal of Scientific & Technical Research is an open access medical and clinical research publication that gives acclaimed scientific authors and research experts a global platform to share their work among like-minded peers and help accumulate scientific knowledge in a singular repository.
- Open Access
- 6 January 2017
- Published by MedCrave Group Kft. in Journal of Cancer Prevention & Current Research
- Vol. 7 (1) , 1-2
Drivers of Precision Medicine: Liquid Biopsy and Next-Generation Sequencing
- 6 January 2017
- Published by MedCrave Group Kft. in Journal of Cancer Prevention & Current Research
- Vol. 7 (1) , 1-2
Open AccessDrivers of Precision Medicine: Liquid Biopsy and Next-Generation Sequencing
- Open Access
- 10 June 2016
- Published by Juniper Publishers in Cancer Therapy & Oncology International Journal
- Vol. 1 (5)
Blood-Drop Liquid Biopsy for Monitoring Mutation Load and Therapeutic Responses
- 10 June 2016
- Published by Juniper Publishers in Cancer Therapy & Oncology International Journal
- Vol. 1 (5)
Open AccessBlood-Drop Liquid Biopsy for Monitoring Mutation Load and Therapeutic Responses
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e23189
Massively parallel sequencing of cell-free DNA enriched from a single drop of urine.
E23189 Background: The clinical application of urinary cell-free DNA (cfDNA) based testing is often cumbersome by difficulties in handling and analyzing large sample volumes, poor yield, ultra-short fragments, and low throughput. We have developed a proprietary cfDNA enrichment technology, designed for minimum sample volume, enabling molecular genetic analysis from a single drop of urine. A key feature of this method is its versatility, which potentially can be applied to a variety of body fluids. Non-invasive detection and monitoring of tumor mutations in urinary cfDNA thus can be realized by combining minimum volume of urine with the high throughput of next-generation sequencing (NGS). Methods: Cell-free DNA was enriched from 20 uL of urine and quantified by fluorometry. The performance of this sample preparation breakthrough was further evaluated by NGS analysis of urinary cfDNA collected from a prospective cohort of 12 subjects. All samples were tested for 2,855 hotspot mutations in 50 well-established cancer driver genes with deep coverage of 2,000X – 14,000X. Results: We have established a novel procedure for urinary cfDNA enrichment with excellent performance in 12 urine samples from volunteers of both genders. In proof-of-concept experiments, the deployment of this protocol provided efficient recovery of urinary cfDNA with yield ranging 382.5 – 6,720 ng by Qubit fluorometer dsDNA assay. The size distribution of the resultant DNA is between 100 – 500 bp. NGS studies demonstrated the consistency of our protocol in generating high usable, on-target, and high-quality ≥ Q20 sequencing reads with good uniformity. We found 100% success rate of sequencing runs by Ion Proton at the allele frequency ≥ 1%. Conclusions: Targeted deep-coverage NGS genomic profiling using cfDNA from a single drop of urine is a highly feasible platform well-suited for routine genetic testing, support of trials with molecularly defined populations, and companion diagnostics in therapeutics development.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e23189
Massively parallel sequencing of cell-free DNA enriched from a single drop of urine.
E23189 Background: The clinical application of urinary cell-free DNA (cfDNA) based testing is often cumbersome by difficulties in handling and analyzing large sample volumes, poor yield, ultra-short fragments, and low throughput. We have developed a proprietary cfDNA enrichment technology, designed for minimum sample volume, enabling molecular genetic analysis from a single drop of urine. A key feature of this method is its versatility, which potentially can be applied to a variety of body fluids. Non-invasive detection and monitoring of tumor mutations in urinary cfDNA thus can be realized by combining minimum volume of urine with the high throughput of next-generation sequencing (NGS). Methods: Cell-free DNA was enriched from 20 uL of urine and quantified by fluorometry. The performance of this sample preparation breakthrough was further evaluated by NGS analysis of urinary cfDNA collected from a prospective cohort of 12 subjects. All samples were tested for 2,855 hotspot mutations in 50 well-established cancer driver genes with deep coverage of 2,000X – 14,000X. Results: We have established a novel procedure for urinary cfDNA enrichment with excellent performance in 12 urine samples from volunteers of both genders. In proof-of-concept experiments, the deployment of this protocol provided efficient recovery of urinary cfDNA with yield ranging 382.5 – 6,720 ng by Qubit fluorometer dsDNA assay. The size distribution of the resultant DNA is between 100 – 500 bp. NGS studies demonstrated the consistency of our protocol in generating high usable, on-target, and high-quality ≥ Q20 sequencing reads with good uniformity. We found 100% success rate of sequencing runs by Ion Proton at the allele frequency ≥ 1%. Conclusions: Targeted deep-coverage NGS genomic profiling using cfDNA from a single drop of urine is a highly feasible platform well-suited for routine genetic testing, support of trials with molecularly defined populations, and companion diagnostics in therapeutics development.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16579
Circulating cell-free DNA profiling for potentially actionable targets in metastatic castration resistant prostate cancer (mCRPC) using next-generation sequencing on droplet volumes of plasma.
E16579 Background: Current methods to extract DNA from plasma are limited by the harvesting of small quantities of poor quality DNA. Circulogene Theranostics has developed a CLIA-certified proprietary method enabling the recovery of necrosis and apoptosis-associated, cell-free (cf)-DNA, with a high-yield ( > 300 ng/ml) of sequencing quality DNA from a drop of plasma. We report cfDNA sequencing data from mCRPC patients (pts) using this novel methodology. Methods: Pts with mCRPC underwent prospective blood collection at UAB. Twenty microliters of plasma collected in a microtainer EDTA tube was used for the harvesting of cfDNA. An automated workstation that can process up to 96 samples facilitates consistent and reliable studies with a turnaround time of 7-10 days. DNA is subjected to targeted ultra-deep (2,000X – 15,000X) Next Generation Sequencing (NGS) on the Ion Torrent platform to detect approximately 3000 hotspot mutations in 50 potentially actionable genes. Germline and unconfirmed/silent somatic mutations and mutations with allele frequency < 1% are filtered out based on dbSNP, 1000 genomes and COSMIC. Results: Plasma samples were available from 27 patients with mCRPC. A median of 840 ng (range 280-1640) of DNA was recovered from 20 µL of plasma per patient. The most common mutation at baseline was in the P53 gene, seen in 7 pts (25.9%), followed by KIT in 3 pts (11.1%) and VEGFR2 in 2 pts (7.4%). Mutations seen in 1 patient each (3.7%) were ALK, CTNNB1, EGFR, ERBB4, FGFR3, HNF1A, HRAS, IDH1, JAK3, KRAS, NOTCH1, PIK3CA, PTEN, PTPN11, RET, SMAD4 and VHL. Activating mutations were seen in ALK, HRAS, IDH1, JAK3 and VEGFR2, and inactivating mutations were seen in P53, PTEN and VHL. The dataset is expanding and results will be updated from a larger number of pts. Conclusions: Multiple potentially actionable therapeutic targets were identified by cfDNA sequencing of pts with mCRPC. This novel methodology facilitates the yield of large quantities of high fidelity DNA from minimal quantities of plasma, and appears promising to serially and non-invasively profile tumor DNA and inform on clonal evolution in a time and cost-efficient manner.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16579
Circulating cell-free DNA profiling for potentially actionable targets in metastatic castration resistant prostate cancer (mCRPC) using next-generation sequencing on droplet volumes of plasma.
E16579 Background: Current methods to extract DNA from plasma are limited by the harvesting of small quantities of poor quality DNA. Circulogene Theranostics has developed a CLIA-certified proprietary method enabling the recovery of necrosis and apoptosis-associated, cell-free (cf)-DNA, with a high-yield ( > 300 ng/ml) of sequencing quality DNA from a drop of plasma. We report cfDNA sequencing data from mCRPC patients (pts) using this novel methodology. Methods: Pts with mCRPC underwent prospective blood collection at UAB. Twenty microliters of plasma collected in a microtainer EDTA tube was used for the harvesting of cfDNA. An automated workstation that can process up to 96 samples facilitates consistent and reliable studies with a turnaround time of 7-10 days. DNA is subjected to targeted ultra-deep (2,000X – 15,000X) Next Generation Sequencing (NGS) on the Ion Torrent platform to detect approximately 3000 hotspot mutations in 50 potentially actionable genes. Germline and unconfirmed/silent somatic mutations and mutations with allele frequency < 1% are filtered out based on dbSNP, 1000 genomes and COSMIC. Results: Plasma samples were available from 27 patients with mCRPC. A median of 840 ng (range 280-1640) of DNA was recovered from 20 µL of plasma per patient. The most common mutation at baseline was in the P53 gene, seen in 7 pts (25.9%), followed by KIT in 3 pts (11.1%) and VEGFR2 in 2 pts (7.4%). Mutations seen in 1 patient each (3.7%) were ALK, CTNNB1, EGFR, ERBB4, FGFR3, HNF1A, HRAS, IDH1, JAK3, KRAS, NOTCH1, PIK3CA, PTEN, PTPN11, RET, SMAD4 and VHL. Activating mutations were seen in ALK, HRAS, IDH1, JAK3 and VEGFR2, and inactivating mutations were seen in P53, PTEN and VHL. The dataset is expanding and results will be updated from a larger number of pts. Conclusions: Multiple potentially actionable therapeutic targets were identified by cfDNA sequencing of pts with mCRPC. This novel methodology facilitates the yield of large quantities of high fidelity DNA from minimal quantities of plasma, and appears promising to serially and non-invasively profile tumor DNA and inform on clonal evolution in a time and cost-efficient manner.
- Open Access
- 27 July 2015
- Published by MedCrave Group Kft. in MOJ Cell Science & Report
- Vol. 2 (3) , 1-2
Next-Generation Sequencing and Targeted Cancer Therapy
- 27 July 2015
- Published by MedCrave Group Kft. in MOJ Cell Science & Report
- Vol. 2 (3) , 1-2
Open AccessNext-Generation Sequencing and Targeted Cancer Therapy